StockData

Cerenome vs RenovoRx

CNSY and RNXT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNSY and RNXT compare

RenovoRx is the larger company, worth 7.9 times as much as Cerenome ($43.1M against $5.4M).

Cerenome keeps more of each dollar of sales as profit, with a net margin of −621% compared with −622% at RenovoRx.

Cerenome scores higher on the StockData Score (8 against 6 for RenovoRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNSYRNXT
Size and price
Market cap$5.4M$43.1M
Share price$0.715$0.955
Change, 1 year−94.5%−2.0%
Change, 5 years−98.1%−85.1%
Beta (5Y)4.791.24
Employees2817
StockData Score
Total score8 (better)6
Valuation score3 (better)0
Growth score11
Performance score00
Health score45 (better)
Dividend score00
Valuation
P/S1.3× (better)21.8×
P/B1.0× (better)4.8×
FCF yield−434%−27.7% (better)
Fair value$2.20–
Margin of safety67.5%–
Growth
Revenue growth (TTM)−21.0%–
Profitability
Gross margin–84.4%
Operating margin−628% (better)−685%
Net margin−621% (better)−622%
FCF margin−560% (better)−604%
Return on equity−614%−125% (better)
Financial health
Debt / equity0.000.00
Interest coverage−1200.0×–
Current ratio1.375.74 (better)
Altman Z-score−58.32−0.69 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions8.3%20.4%
Held by insiders4.2%6.0%
Insider net buying, 12 months$0$66.9K (better)
Short interest, % of float11.6%2.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.